Literature DB >> 20649610

Iloprost has potent anti-inflammatory properties on human monocyte-derived dendritic cells.

T Müller1, T Dürk, B Blumenthal, Y Herouy, S Sorichter, M Grimm, E Panther, S Cicko, J Norgauer, M Idzko.   

Abstract

BACKGROUND: The stable prostaglandin I2 analogue (iloprost) iloprost has been shown to inhibit allergic airway inflammation in mice by modulating the function of myeloid dendritic cells (DCs).
OBJECTIVE: The aim of the current study was to investigate the biological activity of iloprost on human monocyte-derived DCs.
METHODS: I prostanoid (IP) receptor expression was analysed by RT-PCR. Cytokine secretion by DCs and CD4+ T cells was measured by ELISA. The expression of the transcription factor FoxP3 after co-culture of DCs with CD4+ CD45RA+ T cells was analysed by flow cytometry.
RESULTS: Human monocyte-derived DCs were found to express mRNA specific for the PGI2 receptor IP, and stimulation with iloprost resulted in increased cyclic AMP levels in both immature DCs (iDCs) and mature DCs (mDCs). Moreover, iloprost dose dependently inhibited the secretion of TNF-alpha, IL-6, IL-8 and IL-12p70 in mDCs, while it enhanced IL-10 production. Changes in cytokine secretion were paralleled by an altered T-cell priming capacity of DCs: in co-culture experiments of iloprost-treated mDC and naïve CD45RA+ T cells, an induction of regulatory T cells could be observed, as demonstrated by increased intracellular FoxP3 expression and IL-10 production. Additionally, iloprost inhibited the MIP-3beta-induced migration of mDCs.
CONCLUSION: In summary, our results provide evidence that iloprost profoundly affects the function of human myeloid DCs. Therefore, iloprost might also be a new therapeutical option for the treatment of asthma in humans.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20649610     DOI: 10.1111/j.1365-2222.2010.03558.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  12 in total

1.  Iloprost for asthma.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2011-01       Impact factor: 4.599

Review 2.  Control of local immunity by airway epithelial cells.

Authors:  M Weitnauer; V Mijošek; A H Dalpke
Journal:  Mucosal Immunol       Date:  2015-12-02       Impact factor: 7.313

3.  Effect of prostaglandin I2 analogs on cytokine expression in human myeloid dendritic cells via epigenetic regulation.

Authors:  Chang-Hung Kuo; Ching-Hsiung Lin; San-Nan Yang; Ming-Yii Huang; Hsiu-Lin Chen; Po-Lin Kuo; Ya-Ling Hsu; Shau-Ku Huang; Yuh-Jyh Jong; Wan-Ju Wei; Yi-Pin Chen; Chih-Hsing Hung
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

Review 4.  The role of prostaglandins in allergic lung inflammation and asthma.

Authors:  Dru Claar; Tina V Hartert; Ray Stokes Peebles
Journal:  Expert Rev Respir Med       Date:  2014-12-26       Impact factor: 3.772

Review 5.  Prostaglandins in asthma and allergic diseases.

Authors:  R Stokes Peebles
Journal:  Pharmacol Ther       Date:  2018-08-03       Impact factor: 12.310

6.  Iloprost modulates the immune response in systemic sclerosis.

Authors:  Patrizia D'Amelio; Maria A Cristofaro; Lucia D'Amico; Luciana Veneziano; Ilaria Roato; Francesca Sassi; Giuseppina Bisignano; Marta Saracco; Raffaele Pellerito; Salvatore Patanè; Riccardo Ferracini; Gian P Pescarmona; Giovanni C Isaia
Journal:  BMC Immunol       Date:  2010-12-15       Impact factor: 3.615

7.  Endothelial prostacyclin protects the kidney from ischemia-reperfusion injury.

Authors:  Yingxue Cao; Yi Guan; Yun-Yu Xu; Chuan-Ming Hao
Journal:  Pflugers Arch       Date:  2018-11-09       Impact factor: 3.657

8.  Immune Modulation to Enhance Bone Healing-A New Concept to Induce Bone Using Prostacyclin to Locally Modulate Immunity.

Authors:  Sebastian Wendler; Claudia Schlundt; Christian H Bucher; Jan Birkigt; Christian J Schipp; Hans-Dieter Volk; Georg N Duda; Katharina Schmidt-Bleek
Journal:  Front Immunol       Date:  2019-04-05       Impact factor: 7.561

9.  The effect of prostacyclin infusion on markers of endothelial activation and damage in mechanically ventilated patients with SARS-CoV-2 infection.

Authors:  Martin Vigstedt; Peter Søe-Jensen; Morten H Bestle; Niels E Clausen; Klaus T Kristiansen; Theis Lange; Jakob Stensballe; Anders Perner; Pär I Johansson
Journal:  J Crit Care       Date:  2022-02-17       Impact factor: 4.298

Review 10.  PGI2 as a regulator of inflammatory diseases.

Authors:  Stacy L Dorris; R Stokes Peebles
Journal:  Mediators Inflamm       Date:  2012-07-18       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.